| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ADAM-TS7; ADAMTS-7; ADAM-TS 7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ADAMTS7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ADAMTS7抗体的示例参考文献(内容为虚构，仅供格式参考)：
---
1. **文献名称**: *ADAMTS7 Inhibition Attenuates Atherosclerotic Plaque Formation*
**作者**: Smith J, et al. (2020)
**摘要**: 研究证明ADAMTS7在血管平滑肌细胞迁移中起关键作用。通过开发特异性中和抗体，显著抑制小鼠动脉粥样硬化斑块进展，提示其治疗潜力。
2. **文献名称**: *Monoclonal Antibody Targeting ADAMTS7 Reduces Cartilage Degradation in Osteoarthritis*
**作者**: Lee H, et al. (2018)
**摘要**: 该研究制备了靶向ADAMTS7的单克隆抗体，体外实验显示其有效阻断酶活性，减少软骨基质降解，为骨关节炎治疗提供新策略。
3. **文献名称**: *ADAMTS7 Autoantibodies as Biomarkers in Rheumatoid Arthritis*
**作者**: Garcia R, et al. (2021)
**摘要**: 发现类风湿性关节炎患者血清中存在ADAMTS7自身抗体，抗体水平与疾病活动度相关，提示其作为诊断或预后标志物的可能性。
4. **文献名称**: *Structural Characterization of ADAMTS7 via Antibody-Based Epitope Mapping*
**作者**: Wang Y, et al. (2019)
**摘要**: 通过抗体表位定位技术解析ADAMTS7的功能结构域，揭示其底物结合区域，为开发高特异性治疗抗体奠定基础。
---
(注：以上文献及作者为虚构示例，实际引用需查询真实数据库如PubMed、Web of Science。)
The ADAMTS7 antibody is a research tool designed to detect and study ADAMTS7. a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family of extracellular proteases. ADAMTS7 is implicated in extracellular matrix (ECM) remodeling, inflammation, and pathologies such as osteoarthritis, atherosclerosis, and cancer. Its enzymatic activity degrades cartilage oligomeric matrix protein (COMP) and other ECM components, influencing tissue structure and cellular signaling. Dysregulation of ADAMTS7 is linked to vascular calcification, joint degeneration, and tumor progression, making it a potential therapeutic target.
Antibodies against ADAMTS7 are commonly used in techniques like immunohistochemistry, Western blotting, and ELISA to assess protein expression, localization, and activity in biological samples. These antibodies often target specific domains, such as the catalytic metalloproteinase domain or thrombospondin type-1 motifs, enabling functional studies on protease activity or protein-protein interactions. Monoclonal and polyclonal variants are commercially available, with validation data confirming specificity in human, mouse, or rat models.
Recent studies highlight ADAMTS7's role in cardiovascular diseases, particularly atherosclerosis, where its overexpression correlates with plaque instability. In arthritis, it contributes to cartilage breakdown, spurring interest in inhibitory antibodies for disease modification. Researchers also explore its utility as a biomarker for disease progression. However, challenges remain in understanding its full mechanistic spectrum and optimizing antibody-based therapies. Ongoing work aims to clarify its dual roles in tissue homeostasis and pathology, driving demand for reliable ADAMTS7-targeting reagents.
×
